keyword
https://read.qxmd.com/read/38534929/does-pre-emptive-availability-of-predict-2-1-results-change-ordering-practices-for-oncotype-dx-a-multi-center-prospective-cohort-study
#1
JOURNAL ARTICLE
Arif Ali Awan, Deanna Saunders, Gregory Pond, Caroline Hamm, Nadia Califaretti, Mihaela Mates, Vikaash Kumar, Mohammed F K Ibrahim, Ana-Alicia Beltran-Bless, Lisa Vandermeer, John Hilton, Mark Clemons
For early-stage hormone receptor (HR)-positive and HER2-negative breast cancer, tools to estimate treatment benefit include free and publicly available algorithms (e.g., PREDICT 2.1) and expensive molecular assays (e.g., Oncotype DX). There remains a need to identify patients who de-rive the most benefit from molecular assays and where this test may be of poor value. In this multicenter prospective cohort study, we evaluated whether use of PREDICT 2.1 would impact physician decision making. For the first 6 months of the study, data on physician use of both PREDICT 2...
February 27, 2024: Current Oncology
https://read.qxmd.com/read/38525718/tissue-based-genomic-testing-in-prostate-cancer-10-year-analysis-of-national-trends-on-the-use-of-prolaris-decipher-promark-and-oncotype-dx
#2
JOURNAL ARTICLE
Eugenio Bologna, Francesco Ditonno, Leslie Claire Licari, Antonio Franco, Celeste Manfredi, Spencer Mossack, Savio Domenico Pandolfo, Cosimo De Nunzio, Giuseppe Simone, Costantino Leonardo, Giorgio Franco
BACKGROUND: Prostate cancer (PCa) management is moving towards patient-tailored strategies. Advances in molecular and genetic profiling of tumor tissues, integrated with clinical risk assessments, provide deeper insights into disease aggressiveness. This study aims to offer a comprehensive overview of the pivotal genomic tests supporting PCa treatment decisions, analyzing-through real-world data-trends in their use and the growth of supporting literature evidence. METHODS: A retrospective analysis was conducted using the extensive PearlDiver™ Mariner database, which contains de-identified patient records, in compliance with the Health Insurance Portability and Accountability Act (HIPAA)...
March 19, 2024: Clinics and Practice
https://read.qxmd.com/read/38520994/is-oncotype-dx-testing-informative-for-breast-cancers-with-low-er-expression-a-retrospective-review-from-a-biomarker-testing-referral-center
#3
JOURNAL ARTICLE
John Loggie, Penelope J Barnes, Michael D Carter, Daniel Rayson, Gillian C Bethune
PURPOSE: It remains unclear whether patients with HER2-negative, low-estrogen receptor (ER-low)-positive early breast cancer (BC) benefit from Oncotype DX® (ODX) testing. METHODS: We conducted a retrospective review of cases referred for ODX testing over a seven-year period from a breast biomarker testing referral center (n = 854). For each case, we recorded the ODX Recurrence Score (RS) along with percentage of ER nuclear positivity and staining intensity on immunohistochemistry...
March 19, 2024: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/38517602/racial-disparities-in-initiation-of-chemotherapy-among-breast-cancer-patients-with-discretionary-treatment-indication-in-the-state-of-georgia
#4
JOURNAL ARTICLE
Lindsay J Collin, Jade Jones, Rebecca Nash, Jeffrey M Switchenko, Kevin C Ward, Lauren E McCullough
PURPOSE: The majority of breast cancer patients are diagnosed with early-stage estrogen receptor (ER) positive disease. Despite effective treatments for these cancers, Black women have higher mortality than White women. We investigated demographic and clinical factors associated with receipt of chemotherapy among those with a discretionary indication who are at risk for overtreatment. METHODS: Using Georgia Cancer Registry data, we identified females diagnosed with ER positive breast cancer who had a discretionary indication for chemotherapy (2010-2017)...
March 22, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38516286/oncotype-dx-in-breast-cancer-management-insights-and-outcomes-from-the-united-arab-emirates
#5
JOURNAL ARTICLE
Mouza A Ameri, Nandan M Shanbhag, Abdulrahman Bin Sumaida, Jawaher Ansari, Diaeddine A Trad, Emad A Dawoud, Khalid Balaraj
Introduction Breast cancer remains the most significant cancer affecting women worldwide, with an increasing incidence, especially in developing regions. The introduction of genomic tests like Oncotype DX has revolutionized personalized treatment, allowing for more tailored approaches to therapy. This study focuses on the United Arab Emirates (UAE), where breast cancer is the leading cause of cancer-related deaths among women, aiming to assess the predictive accuracy of the Oncotype DX test in categorizing patients based on recurrence risk...
March 2024: Curēus
https://read.qxmd.com/read/38489298/a-randomised-controlled-trial-of-pre-operative-oncotype-dx-testing-in-early-stage-breast-cancer-pre-dx-study-study-protocol
#6
JOURNAL ARTICLE
Matthew Northgraves, Judith Cohen, James Harvey, Chao Huang, Carlo Palmieri, Sarah Pinder, Pankaj Roy, Sarah Reynia, Marta Soares, Henry Cain
BACKGROUND: The Oncotype DX® Breast Recurrence Score assay can guide recommendations made to patients with oestrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer regarding post-surgery adjuvant therapy. Standard practice is to order the test in the post-operative setting on a specimen from the excised invasive carcinoma. However, it has been shown to be technically possible to perform the test on the diagnostic core biopsy. By testing the diagnostic core biopsy in the pre-operative setting, the wait for excised invasive carcinoma Recurrence Score results could be reduced allowing patients to be more accurately counselled regarding their treatment pathway sooner with any adjuvant treatment recommendations expedited...
2024: PloS One
https://read.qxmd.com/read/38451415/correlation-between-postoperative-treatment-selection-and-prognosis-determined-using-the-oncotype-dx%C3%A2-test-data-a-retrospective-multicenter-study-in-japan
#7
JOURNAL ARTICLE
Yasue Tsuchida, Naoki Niikura, Takashi Chishima, Mari Mizuno, Takahiko Kawate, Hiromi Fuchikami, Yasuo Miyoshi, Takehiko Sakai, Haruru Kotani, Naoto Kondo, Naoki Hayashi
PURPOSE: Oncotype DX® is a frequently used multigene assay for hormone receptor-positive breast cancers. However, limited evidence is available regarding its application in Japan owing to the lack of insurance coverage. Therefore, we conducted this large-scale, retrospective study by collecting data from nine Japanese institutes and assessed postoperative treatment choice and prognosis by using Oncotype DX®. METHODS: Six hundred thirty-two patients who underwent breast surgery and whose recurrence score (RS) data were available were included...
March 7, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://read.qxmd.com/read/38439804/the-role-of-modern-parameters-and-their-relationship-with-recurrence-risk-as-assessed-by-oncotype-dx-real-world-evidence
#8
JOURNAL ARTICLE
Dana Narvaez, Jorge Nadal, Adrian Nervo, Victoria Costanzo, Claudio Paletta, Fernando Petracci, Sergio Rivero, Alexis Ostinelli, Federico Coló, Loza Martín, Veronica Fabiano, Luciana Sabatini, Azul Perazzolo, Mora Amat, Matias Chacon, Federico Waisberg
Genomic analysis through various platforms is an essential tool for determining prognosis and treatment in a significant subgroup of early-stage breast cancer patients with hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative status. Additionally, combined clinical and pathological characteristics can accurately predict the recurrence score (RS), as demonstrated by the University of Tennessee risk nomogram. In this study, we aimed to identify classical clinical-pathological factors associated with high RS in a local population, including modern parameters such as current abemaciclib treatment recommendations, HER2-low status, different Ki-67 cutoff values, and samples obtained from secondary primary tumours...
2024: Ecancermedicalscience
https://read.qxmd.com/read/38436289/a-cost-consequence-model-of-using-the-21-gene-assay-to-identify-patients-with-early-stage-node-positive-breast-cancer-who-benefit-from-adjuvant-chemotherapy-in-the-netherlands
#9
JOURNAL ARTICLE
Martijn J H G Simons, Peter M Machielsen, Jelle A Spoorendonk, Tim Ignacio, Pieter B Drost, Tim Jacobs, Felix E deJongh
INTRODUCTION: Patients with early-stage hormone receptor positive, human epidermal growth factor receptor-2 (HER2) negative invasive breast cancer with 1-3 positive lymph nodes (N1) often undergo surgical excisions followed by adjuvant chemotherapy (ACT). Many patients have no benefit from ACT and receive unnecessary, costly treatment often associated with short- and long-term adverse events (AEs). Gene expression profiling (GEP) assays, such as the 21-gene assay (i.e., the Oncotype DX assay), can identify patients at higher risk for recurrence who may benefit from ACT...
March 4, 2024: Journal of Medical Economics
https://read.qxmd.com/read/38398165/prediction-of-a-multi-gene-assay-oncotype-dx-and-mammaprint-recurrence-risk-group-using-machine-learning-in-estrogen-receptor-positive-her2-negative-breast-cancer-the-brain-study
#10
JOURNAL ARTICLE
Jung-Hwan Ji, Sung Gwe Ahn, Youngbum Yoo, Shin-Young Park, Joo-Heung Kim, Ji-Yeong Jeong, Seho Park, Ilkyun Lee
This study aimed to develop a machine learning-based prediction model for predicting multi-gene assay (MGA) risk categories. Patients with estrogen receptor-positive (ER+)/HER2- breast cancer who had undergone Oncotype DX (ODX) or MammaPrint (MMP) were used to develop the prediction model. The development cohort consisted of a total of 2565 patients including 2039 patients tested with ODX and 526 patients tested with MMP. The MMP risk prediction model utilized a single XGBoost model, and the ODX risk prediction model utilized combined LightGBM, CatBoost, and XGBoost models through soft voting...
February 13, 2024: Cancers
https://read.qxmd.com/read/38384494/budget-impact-of-the-oncotype-dx-breast-recurrence-score-%C3%A2-test-in-patients-with-early-primary-hormone-receptor-positive-her2-negative-node-positive-breast-cancer-in-germany
#11
JOURNAL ARTICLE
Michael Patrick Lux, Christof Minartz, Harald Müller-Huesmann, Marianar Felicia Sandor, Sabine Radeck-Knorre, Aljoscha Steffen Neubauer
BACKGROUND: Gene expression tests can inform decisions on whether to recommend or omit chemotherapy for patients with early HR+, HER2- breast cancer. The benefit of these tests is well established and fully reimbursed by sickness funds for lymph node-negative (pN0) patients in Germany. A budget impact model was built to evaluate the effect of using the Oncotype DX Breast Recurrence Score® test also for node-positive (pN1: 1-3 positive lymph nodes) patients. METHODS: The prospective randomized clinical trial, RxPONDER, defined conditions (Recurrence Score result 0-25 for postmenopausal patients with 1-3 positive lymph nodes) under which omitting chemotherapy does not significantly impact invasive disease-free survival with results currently reported for 5-year follow-up...
February 2024: Breast Care
https://read.qxmd.com/read/38367283/21-gene-recurrence-score-in-predicting-the-outcome-of-postoperative-radiotherapy-in-t1-2n1-luminal-breast-cancer-after-breast-conserving-surgery
#12
JOURNAL ARTICLE
Shang-Jin Xie, Run-Jie Wang, San-Gang Wu, Fu-Xing Zhang
BACKGROUND: In those with one to three positive lymph nodes (N1) breast cancer (BC), the 21-gene recurrence score (RS) classification can be referred for decision-making on adjuvant chemotherapy. This study aimed to investigate the effect of RS in predicting the survival benefit of postoperative radiotherapy (PORT) in T1-2N1 BC with estrogen receptor-positive and human epidermal growth factor receptor 2-negative disease after breast-conserving surgery (BCS). METHODS: We included patients with BC and available RS data from the Surveillance, Epidemiology, and End Results Oncotype DX database...
February 12, 2024: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/38359680/anatomy-versus-biology-what-guides-chemotherapy-decisions-in-older-patients-with-breast-cancer
#13
JOURNAL ARTICLE
Sydney M Record, Samantha M Thomas, William M Tian, Astrid Botty van den Bruele, Akiko Chiba, Gayle DiLalla, Maggie L DiNome, Gretchen Kimmick, Laura H Rosenberger, Hannah E Woriax, E Shelley Hwang, Jennifer K Plichta
INTRODUCTION: With the increasing utilization of genomic assays, such as the Oncotype DX recurrence score (RS), the relevance of anatomic staging has been questioned for select older patients with breast cancer. We sought to evaluate differences in chemotherapy receipt and/or survival among older patients based on RS and sentinel lymph node biopsy (SLNB) receipt/result. METHODS: Patients aged ≥ 65 diagnosed with pT1-2/cN0/M0 hormone-receptor-positive (HR+)/HER2-breast cancer (2010-2019) were selected from the National Cancer Database...
February 14, 2024: Journal of Surgical Research
https://read.qxmd.com/read/38350748/axillary-nodal-disease-burden-is-not-associated-with-an-elevated-21-gene-recurrence-score-in-post-menopausal-women-presenting-with-a-clinically-negative-axilla
#14
JOURNAL ARTICLE
Astrid Botty van den Bruele, Morgan A Paul, Samantha M Thomas, Sarah L Sammons, Maggie L DiNome, Jennifer K Plichta, Sydney M Record, Hannah Woriax, Akiko Chiba, Laura H Rosenberger, E Shelley Hwang
BACKGROUND: The predictive and prognostic value of the recurrence score (RS) has emphasized the importance of tumor biology and has reduced the prognostic implications of limited nodal burden in post-menopausal women with HR+/HER2-invasive breast cancer (IBC). It is unclear whether routine axillary staging has a continued role in the management of small, clinically node negative (cN0) HR+/HER2- IBC. We sought to estimate the association of RS with pN stage. METHODS: Patients >50yo diagnosed with cN0, HR+/HER2- IBC (2015-2019) with an available RS were identified from the National Cancer Database...
February 6, 2024: American Journal of Surgery
https://read.qxmd.com/read/38344872/ncaph-drives-breast-cancer-progression-and-identifies-a-gene-signature-that-predicts-luminal-a-tumour-recurrence
#15
JOURNAL ARTICLE
Marina Mendiburu-Eliçabe, Natalia García-Sancha, Roberto Corchado-Cobos, Angélica Martínez-López, Hang Chang, Jian Hua Mao, Adrián Blanco-Gómez, Ana García-Casas, Andrés Castellanos-Martín, Nélida Salvador, Alejandro Jiménez-Navas, Manuel Jesús Pérez-Baena, Manuel Adolfo Sánchez-Martín, María Del Mar Abad-Hernández, Sofía Del Carmen, Juncal Claros-Ampuero, Juan Jesús Cruz-Hernández, César Augusto Rodríguez-Sánchez, María Begoña García-Cenador, Francisco Javier García-Criado, Rodrigo Santamaría Vicente, Sonia Castillo-Lluva, Jesús Pérez-Losada
BACKGROUND: Luminal A tumours generally have a favourable prognosis but possess the highest 10-year recurrence risk among breast cancers. Additionally, a quarter of the recurrence cases occur within 5 years post-diagnosis. Identifying such patients is crucial as long-term relapsers could benefit from extended hormone therapy, while early relapsers might require more aggressive treatment. METHODS: We conducted a study to explore non-structural chromosome maintenance condensin I complex subunit H's (NCAPH) role in luminal A breast cancer pathogenesis, both in vitro and in vivo, aiming to identify an intratumoural gene expression signature, with a focus on elevated NCAPH levels, as a potential marker for unfavourable progression...
February 2024: Clinical and Translational Medicine
https://read.qxmd.com/read/38316810/software-breastanalyser-for-the-semi-automatic-analysis-of-breast-cancer-immunohistochemical-images
#16
JOURNAL ARTICLE
Marina Rodríguez-Candela Mateos, Maria Azmat, Paz Santiago-Freijanes, Eva María Galán-Moya, Manuel Fernández-Delgado, Rosa Barbella Aponte, Joaquín Mosquera, Benigno Acea, Eva Cernadas, María D Mayán
Breast cancer is the most diagnosed cancer worldwide and represents the fifth cause of cancer mortality globally. It is a highly heterogeneous disease, that comprises various molecular subtypes, often diagnosed by immunohistochemistry. This technique is widely employed in basic, translational and pathological anatomy research, where it can support the oncological diagnosis, therapeutic decisions and biomarker discovery. Nevertheless, its evaluation is often qualitative, raising the need for accurate quantitation methodologies...
February 6, 2024: Scientific Reports
https://read.qxmd.com/read/38308000/a-uk-prospective-multicentre-decision-impact-decision-conflict-and-economic-evaluation-of-the-21-gene-assay-in-women-with-node-ve-hormone-receptor-ve-her2-ve-breast-cancer
#17
JOURNAL ARTICLE
Simon Holt, Mark Verrill, Laura Pettit, Anna Rigg, Tamas Hickish, Caroline Archer, Jo Dent, Marianne Dillon, Mark Nathan, Ludger Barthelmes, Shazza Rehman, Yousef Sharaiha, Paige Innis, Priya Sai-Giridhar, Saira Khawaja
BACKGROUND: For a tumour profiling test to be of value, it needs to demonstrate that it is changing clinical decisions, improving clinical confidence, and of economic benefit. This trial evaluated the use of the Oncotype DX Breast Recurrence Score® assay against these criteria in 680 women with hormone receptor-positive (HR+), HER2-negative early breast cancer with 1-3 lymph nodes positive (LN+) in the UK National Health Service (NHS). METHODS: Prior to receipt of the Recurrence Score (RS) result, both the physician and the patient were asked to state their preference for or against chemotherapy and their level of confidence on a scale of 1-5...
February 2, 2024: British Journal of Cancer
https://read.qxmd.com/read/38280206/the-impact-of-genomic-biomarkers-on-a-clinical-risk-prediction-model-for-upgrading-upstaging-among-men-with-favorable-risk-prostate-cancer
#18
JOURNAL ARTICLE
Avery E Braun, June M Chan, John Neuhaus, Janet E Cowan, Stacey A Kenfield, Erin L Van Blarigan, Imelda Tenggara, Jeanette M Broering, Jeffry P Simko, Peter R Carroll, Matthew R Cooperberg
BACKGROUND: The challenge of distinguishing indolent from aggressive prostate cancer (PCa) complicates decision-making for men considering active surveillance (AS). Genomic classifiers (GCs) may improve risk stratification by predicting end points such as upgrading or upstaging (UG/US). The aim of this study was to assess the impact of GCs on UG/US risk prediction in a clinicopathologic model. METHODS: Participants had favorable-risk PCa (cT1-2, prostate-specific antigen [PSA] ≤15 ng/mL, and Gleason grade group 1 [GG1]/low-volume GG2)...
January 27, 2024: Cancer
https://read.qxmd.com/read/38277952/young-age-as-a-predictor-of-chemotherapy-recommendation-and-treatment-in-breast-cancer-a-national-cancer-database-study
#19
JOURNAL ARTICLE
Elaina Graham, Katie Bennett, Danielle Boselli, Anna Hecksher, Courtney Schepel, Richard L White, Lejla Hadzikadic-Gusic
INTRODUCTION: Breast cancer, although the second most common malignancy in women in the United States, is rare in patients under the age of 40 y. However, this young patient population has high recurrence and mortality rates, with chemotherapy frequently used as adjuvant treatment. We aimed to determine whether age is an independent predictor of chemotherapy recommendation and subsequent treatment and the relationship to Oncotype Dx (ODX) recurrence score (RS). METHODS: The National Cancer Database was retrospectively reviewed from 2010-2016 to identify women with early-stage (pT1-pT3, pN0-pN1mic, M0), hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer who underwent ODX RS testing...
January 25, 2024: Journal of Surgical Research
https://read.qxmd.com/read/38265569/real-world-use-of-multigene-signatures-in-early-breast-cancer-differences-to-clinical-trials
#20
JOURNAL ARTICLE
Luca Licata, Rita De Sanctis, Andrea Vingiani, Deborah Cosentini, Monica Iorfida, Elena Rota Caremoli, Isabella Sassi, Bethania Fernandes, Andrea Gianatti, Elena Guerini-Rocco, Claudia Zambelli, Elisabetta Munzone, Edda Lucia Simoncini, Carlo Tondini, Oreste Davide Gentilini, Alberto Zambelli, Giancarlo Pruneri, Giampaolo Bianchini
PURPOSE: In Italy, Lombardy was the first region to reimburse multigene assays (MGAs) for patients otherwise candidates for chemotherapy. This is a real-world experience of MGAs usage in six referral cancer centers in Lombardy. METHODS: Among MGAs, Oncotype DX (RS) was used in 97% of cases. Consecutive patients tested with Oncotype DX from July 2020 to July 2022 were selected. The distribution of clinicopathologic features by RS groups (low RS: 0-25, high RS: 26-100) was assessed using chi-square and compared with those of the TAILORx and RxPONDER trials...
January 24, 2024: Breast Cancer Research and Treatment
keyword
keyword
24782
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.